Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | PNP | P00491 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HBB | P68871 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7032887 | 0.83 | GRIN2D (0.38) | TYMPALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL29592452 | 0.83 | IDH1 (0.36) | IDH1CSNK2A2CSNK2BCSNK2A1TYMP | |
| SCHEMBL21379214 | 0.83 | IDH1 (0.36) | IDH1CSNK2A2CSNK2BCSNK2A1TYMP | |
| SCHEMBL16637455 | 0.83 | IDH1 (0.36) | IDH1CSNK2A2CSNK2BCSNK2A1TYMP | |
| SCHEMBL29388927 | 0.83 | IDH1 (0.36) | IDH1CSNK2A2CSNK2BCSNK2A1TYMP | |
| SCHEMBL24004705 | 0.80 | GRIN2D (0.38) | IDH1CSNK2A2CSNK2BCSNK2A1TYMP | |
| SCHEMBL31542506 | 0.80 | IDH1 (0.34) | IDH1CSNK2A2CSNK2BCSNK2A1TYMP | |
| SCHEMBL25820506 | 0.79 | DPYD (0.38) | IDH1CSNK2A2CSNK2BCSNK2A1TYMP | |
| SCHEMBL31748457 | 0.78 | GRIN2D (0.44) | IDH1CSNK2A2CSNK2BCSNK2A1ALDH1A1 | |
| SCHEMBL25330088 | 0.78 | SIRT2 (0.41) | TYMPALDH1A1LMNAMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276982-A1 | KRAS INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-09-04 | — | — | US | disclosed |
| US-20240246954-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KRAS | THERAS, INC. | 2024-07-25 | — | — | US | disclosed |
| CN-117794930-A | KRAS inhibitors | 苏州亚盛药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024061365-A1 | PYRIMIDINE FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 成都奥睿药业有限公司 | 2024-03-28 | — | — | WO | disclosed |
| EP-4294799-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | Theras Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-117157290-A | Compositions and methods for inhibiting KRAS | 瑟拉斯有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023125989-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023030495-A1 | KRAS INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-03-09 | — | — | WO | disclosed |
| WO-2022177917-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246954-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KRAS | KRAS, NRAS, HRAS | IDH1 71/4885CSNK2A2 769/4885CSNK2B 638/4885 |
| US-20250276982-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | IDH1 235/4885CSNK2A2 2239/4885CSNK2B 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.